Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
Dementia includes many disorders, such as Lewy Body dementia, Alzheimer's disease, vascular dementia, and more
Research focuses include fibroblast migration, collagen production, and nitric oxide modulation
However, data are limited for changes in chronic diseases such as IBD or metabolic disorders
Extended warming may require replacing affected materials
This is different than some other hyaluronic acid fillers, such as Restylane, which does not attract water